Suppr超能文献

最小化纯化方法可用于评估重组蛋白的可开发性。

Minimal purification method enables developability assessment of recombinant proteins.

机构信息

Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

出版信息

Biotechnol Bioeng. 2024 Aug;121(8):2423-2434. doi: 10.1002/bit.28385. Epub 2023 Apr 3.

Abstract

Analytical characterization of proteins is a critical task for developing therapeutics and subunit vaccine candidates. Assessing candidates with a battery of biophysical assays can inform the selection of one that exhibits properties consistent with a given target product profile (TPP). Such assessments, however, require several milligrams of purified protein, and ideal assessments of the physicochemical attributes of the proteins should not include unnatural modifications like peptide tags for purification. Here, we describe a fast two-stage minimal purification process for recombinant proteins secreted by the yeast host Komagataella phaffii from a 20 mL culture supernatant. This method comprises a buffer exchange and filtration with a Q-membrane filter and we demonstrate sufficient removal of key supernatant impurities including host-cell proteins (HCPs) and DNA with yields of 1-2 mg and >60% purity. This degree of purity enables characterizing the resulting proteins using affinity binding, mass spectrometry, and differential scanning calorimetry. We first evaluated this method to purify an engineered SARS-CoV-2 subunit protein antigen and compared the purified protein to a conventional two-step chromatographic process. We then applied this method to compare several SARS-CoV-2 RBD sequences. Finally, we show this simple process can be applied to a range of other proteins, including a single-domain antibody, a rotavirus protein subunit, and a human growth hormone. This simple and fast developability methodology obviates the need for genetic tagging or full chromatographic development when assessing and comparing early-stage protein therapeutics and vaccine candidates produced in K. phaffii.

摘要

蛋白质分析特性是开发治疗药物和亚单位疫苗候选物的关键任务。使用一系列生物物理测定法评估候选物,可以为具有与特定目标产品特性(TPP)一致的特性的候选物的选择提供信息。然而,这些评估需要几毫克的纯化蛋白,并且对蛋白质物理化学性质的理想评估不应包括用于纯化的肽标签等非天然修饰。在这里,我们描述了一种从 20mL 培养上清液中由酵母宿主 Komagataella phaffii 分泌的重组蛋白的快速两阶段最小纯化过程。该方法包括缓冲液交换和 Q 膜过滤器过滤,我们证明了关键上清液杂质(包括宿主细胞蛋白(HCP)和 DNA)的有效去除,收率为 1-2mg,纯度>60%。这种纯度可以使我们使用亲和结合、质谱和差示扫描量热法来表征所得的蛋白质。我们首先评估了这种方法来纯化一种工程 SARS-CoV-2 亚单位蛋白抗原,并将纯化的蛋白质与传统的两步色谱过程进行了比较。然后,我们应用该方法比较了几种 SARS-CoV-2 RBD 序列。最后,我们表明这种简单的过程可以应用于一系列其他蛋白质,包括单域抗体、轮状病毒蛋白亚单位和人生长激素。当评估和比较在 Komagataella phaffii 中生产的早期蛋白质治疗药物和疫苗候选物时,这种简单快速的可开发性方法避免了遗传标记或全色谱开发的需要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验